CytoDyn Inc CYDY

Healthcare Biotechnology

CytoDyn Inc. is a clinical-stage biotechnology company. The Company is focused on the development and commercialization of leronlimab, an investigational humanized IgG4 monoclonal antibody (mAb) that is designed to bind to C-C chemokine receptor type 5 (CCR5), a protein on the surface of certain immune system cells. It has studied leronlimab in multiple therapeutic areas, including infectious disease, oncology, and autoimmune conditions. The Company has conducted clinical trials of leronlimab as a viral entry inhibitor for human immunodeficiency virus (HIV), believed to competitively bind to the N-terminus and second extracellular loop of the CCR5 receptor. For immunology, the CCR5 receptor is believed to be implicated in immune-mediated illnesses such as Metabolic dysfunction-associated steatohepatitis. It has a joint development agreement with a third-party generative artificial intelligence (AI) drug discovery and development company to develop one or more longer-acting molecules.

OTCQB:CYDY - Post by User

CytoDyn Inc

<< Previous

Bullboard Posts

Next >>

Post by theNormon Jan 17, 2021 5:57pm

108 Views

Post# 32316269

Bring on the Nasdaq uplist

A successful treatment for Covid 19 AND a cost effective alternative to stop HIV in it's tracks here.

Back to $10 soon and beyond. FDA under new mgmt Jan 20th All aboard !!!!!!!

<< Previous

Bullboard Posts

Next >>

Unique Battery Metals opportunity in Quebec